Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Handa PharmaceuticalsROCO:6620 -1.28%75 Interest Coverage is 137.18 as of Dec. 2025, which is 93% below its 10-year median of 1,986.63. GuruFocus rates ROCO:6620 with a GF Score™ of 75/100 and a GF Value™ of NT$183.95 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 687 Drug Manufacturers companies, Handa Pharmaceuticals ranks better than 85.44% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Handa Pharmaceuticals's
Operating Income
for the
three
months ended in Dec. 2025 was NT$158.6 Mil. Handa Pharmaceuticals's Interest Expense for the
three
months ended in Dec. 2025 was NT$-1.2 Mil.
Handa Pharmaceuticals's interest coverage for the quarter that ended in Dec. 2025 was 137.18.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Handa Pharmaceuticals Inc has enough cash to cover all of its debt. Its financial situation is stable.
The historical rank and industry rank for Handa Pharmaceuticals's Interest Coverage or its related term are showing as below:
ROCO:6620'
s Interest Coverage Range Over the Past 10 Years
Min: 5.82 Med: 1986.63 Max: 10334.21
Current: 200.14
ROCO:6620's Interest Coverage is ranked better than 85.44% of 687
companies
in the Drug Manufacturers industry
Industry Median: 12.75
vs ROCO:6620: 200.14
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Handa Pharmaceuticals Interest Coverage Related Terms
Handa Pharmaceuticals Interest Coverage Historical Data
* Premium members only.
The historical data trend for Handa Pharmaceuticals's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
ROCO:6620 vs ZTS, UTHR: Interest Coverage Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Handa Pharmaceuticals's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Handa Pharmaceuticals Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Handa Pharmaceuticals's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Handa Pharmaceuticals's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Handa Pharmaceuticals (ROCO:6620) has a Interest Coverage of 137.18 as of Dec. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Handa Pharmaceuticals and its competitors. This is 93% below median its historical median of 1,986.63. Over the past decade, Handa Pharmaceuticals' Interest Coverage has ranged from 5.82 to 10,334.21. According to the industry distribution chart, Handa Pharmaceuticals ranks #100 out of 687 companies in the Drug Manufacturers industry, placing it in the top 14.6%.
Is Handa Pharmaceuticals' Interest Coverage too high?
Handa Pharmaceuticals' current Interest Coverage of 137.18 is 93% below median its 10-year median of 1,986.63. Over the past 10 years, this metric has ranged from a low of 5.82 to a high of 10,334.21. The Drug Manufacturers industry median Interest Coverage is 12.75. Handa Pharmaceuticals' value of 137.18 is 975.9% above this industry median. Based on the distribution chart, Handa Pharmaceuticals ranks #100 out of 687 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Handa Pharmaceuticals has a GF Score™ of 75/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Handa Pharmaceuticals' Interest Coverage compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Handa Pharmaceuticals ranks #100 out of 687 companies for Interest Coverage. This places Handa Pharmaceuticals in the top 15% of its industry — outperforming the majority of peers. The industry median Interest Coverage is 12.75. Handa Pharmaceuticals' value of 137.18 is 975.9% above this benchmark. Historically, Handa Pharmaceuticals' own Interest Coverage has ranged from 5.82 to 10,334.21 over the past decade. While the company's 10-year median is 1,986.63 vs. the industry median of 12.75, Handa Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.75, based on 687 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Handa Pharmaceuticals's current Interest Coverage of 137.18 is 975.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Handa Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Handa Pharmaceuticals's current Interest Coverage is 137.18, which is 93% below median its own 10-year median of 1,986.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Handa Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Handa Pharmaceuticals (ROCO:6620) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$183.95, compared to a current price of NT$84.70 — trading 54% below its estimated fair value. The current Interest Coverage is 137.18, which is 93% below median its 10-year median of 1,986.63 and 975.9% above the Drug Manufacturers industry median of 12.75. Handa Pharmaceuticals' overall GF Score™ is 75/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Handa Pharmaceuticals (ROCO:6620), the current Interest Coverage is 137.18 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Handa Pharmaceuticals (ROCO:6620) Overvalued in 2026?
Based on GuruFocus' analysis, Handa Pharmaceuticals stock appears to be undervalued.
The current stock price of NT$84.70 is trading 54% below its estimated GF Value™ of NT$183.95.
GuruFocus considers Handa Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for ROCO:6620:
Interest Coverage: 137.18 (93% below median its 10-year median of 1,986.63)
GF Value™: NT$183.95 vs. price of NT$84.70 (54% below fair value)
Industry Position: 975.9% above the Drug Manufacturers median (#100 of 687)
No single metric tells the full story. See the ROCO:6620 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Handa Pharmaceuticals Inc is a Taiwan-based specialty pharmaceutical company. It is engaged in the development of niche drugs. The company focuses on the development of high-barrier/patentable niche products.
75GF Score
Get the complete analysis for ROCO:6620
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6620 has been successfully added to your 
